Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $19.37 $25.53 Friday, 10th May 2024 NTLA stock ended at $24.46. This is 1.61% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 4.85% from a day low at $24.25 to a day high of $25.42.
90 days $19.37 $34.87
52 weeks $19.37 $47.48

Historical Intellia Therapeutics Inc prices

Date Open High Low Close Volume
Feb 29, 2024 $33.80 $34.87 $31.70 $32.12 4 051 917
Feb 28, 2024 $30.43 $33.25 $30.28 $32.80 3 118 668
Feb 27, 2024 $28.45 $31.13 $28.01 $31.02 3 283 421
Feb 26, 2024 $25.75 $27.69 $25.69 $27.66 1 778 145
Feb 23, 2024 $26.72 $27.01 $25.49 $26.10 2 104 635
Feb 22, 2024 $26.50 $27.88 $25.33 $27.18 1 944 077
Feb 21, 2024 $27.00 $27.28 $26.26 $26.88 1 679 553
Feb 20, 2024 $27.41 $27.70 $26.80 $27.15 1 315 497
Feb 16, 2024 $27.59 $28.10 $27.06 $27.74 1 631 111
Feb 15, 2024 $27.95 $29.39 $27.01 $28.47 2 659 442
Feb 14, 2024 $27.11 $28.33 $26.43 $28.28 1 549 486
Feb 13, 2024 $27.89 $28.02 $26.07 $26.45 2 406 041
Feb 12, 2024 $28.30 $29.64 $28.20 $29.61 1 295 387
Feb 09, 2024 $27.89 $28.89 $27.47 $28.23 1 076 985
Feb 08, 2024 $26.34 $27.90 $26.01 $27.47 1 185 280
Feb 07, 2024 $26.56 $26.58 $25.71 $26.07 971 247
Feb 06, 2024 $24.86 $26.63 $24.53 $26.57 1 247 629
Feb 05, 2024 $24.81 $25.06 $24.23 $24.84 1 356 027
Feb 02, 2024 $24.44 $25.42 $23.97 $25.29 1 858 583
Feb 01, 2024 $24.03 $25.98 $23.63 $25.26 2 488 184
Jan 31, 2024 $24.52 $25.24 $23.76 $23.82 1 464 723
Jan 30, 2024 $25.81 $25.91 $24.58 $24.59 3 320 801
Jan 29, 2024 $24.76 $26.46 $23.93 $26.18 1 324 119
Jan 26, 2024 $25.48 $26.08 $24.62 $24.68 968 999
Jan 25, 2024 $25.35 $25.87 $25.01 $25.09 1 314 931
Click to get the best stock tips daily for free!

About Intellia Therapeutics Inc

Intellia Therapeutics Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline... NTLA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT